Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00340054 · ClinicalTrials.gov registry record
Developing Interview Questions to Estimate Workplace Exposure to Electric and Magnetic Fields
A clinical trial of Brain and Central Nervous System Tumors, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- 108
- Enrollment target
- 2
- Study locations
NCT00340054: Completed study of Brain and Central Nervous System Tumors, sponsored by National Institutes of Health Clinical Center (CC).
NCT00340054 is a study of Brain and Central Nervous System Tumors that has completed, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 108 participants, below the 181-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (40% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00340054, a study of Brain and Central Nervous System Tumors, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- 108 participants
- Enrollment target
- 2
- Study locations
Study Summary
RATIONALE: Electric and magnetic fields may increase the risk of cancer. Developing interview questions that accurately estimate a person's exposure to electric and magnetic fields may help doctors learn about the long-term effects of workplace exposure. PURPOSE: This clinical trial is developing interview questions that can be used in estimating workplace exposure to electric and magnetic fields.
Conditions Studied
Interventions
- OTHER questionnaire administration
- PROCEDURE study of high risk factors
Study Locations (2)
California
- Exponent, Inc. - Menlo Park
Ohio
- National Institute for Occupational Safety and Health - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2005-10 |
| Est. Completion | 2007-03 |
What the finished NCT00340054 record still lists
NCT00340054 is an observational study that tracks outcomes without assigning an intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 181-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (40% lower).
The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 2 interventions - of which questionnaire administration is the first listed.
NCT00340054 reports a single indexed study location in California, Ohio.
Frequently Asked Questions
What is clinical trial NCT00340054 about?
NCT00340054 is a clinical study titled "Developing Interview Questions to Estimate Workplace Exposure to Electric and Magnetic Fields". RATIONALE: Electric and magnetic fields may increase the risk of cancer. Developing interview questions that accurately estimate a person's exposure to electric and magnetic fields may help doctors learn about the long-term effects of workplace exposure. PURPOSE: This clinical trial is developing i...
What is the current status of trial NCT00340054?
This trial is currently completed. The enrollment target is 108 participants. The study started on 2005-10. Estimated completion is 2007-03.
What conditions does trial NCT00340054 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.
What interventions are being tested in trial NCT00340054?
The interventions under investigation include: questionnaire administration (OTHER), study of high risk factors (PROCEDURE).
Who is sponsoring clinical trial NCT00340054?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00340054 being conducted?
This trial has 2 study locations across California, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00340054's enrollment target sits among peer trials
108 12th of 45 higher than 34 of 45 other Brain and Central Nervous System Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain and Central Nervous System Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
RECRUITING
-
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
ACTIVE NOT RECRUITING · Phase 3
-
Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)
ACTIVE NOT RECRUITING · Phase 3
-
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
ACTIVE NOT RECRUITING · Phase 2
-
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
ACTIVE NOT RECRUITING · Phase 3
-
Immunotoxin Therapy in Treating Patients With Malignant Glioma
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia